Featured Research

from universities, journals, and other organizations

Research shows immune system response is detrimental to novel brain cancer therapy

Date:
December 4, 2012
Source:
Brigham and Women's Hospital
Summary:
For the first time, researchers have demonstrated that the response of natural killer (NK) cells is detrimental to glioblastoma virotherapy, a novel way of treating malignant brain cancer by injecting a virus into the tumor. A number of clinical trials are currently underway to test whether glioblastoma virotherapy will facilitate antitumor efficacy, but new research shows that in pre-clinical models, NK cells are killing off the virus – infected cells, thus rendering the therapy less effective.

For the first time, researchers have demonstrated that the response of natural killer (NK) cells is detrimental to glioblastoma virotherapy, a novel way of treating malignant brain cancer by injecting a virus into the tumor. A number of clinical trials are currently underway to test whether glioblastoma virotherapy will facilitate antitumor efficacy, but research led by E. Antonio Chiocca, MD, PhD, chairman of the Department of Neurosurgery at Brigham and Women's Hospital, and published online on Nov. 25, 2012 in Nature Medicine, shows that in pre-clinical models, NK cells are killing off the virus -- infected cells, thus rendering the therapy less effective.

Related Articles


"This situation is similar to injecting a beneficial drug into a human and the drug is killed off because humans have an antibody against the drug," said Dr. Chiocca, the senior author of the research paper. "This finding will be of great interest to those who are studying experimental biology and tumors of the brain, as well as to patients with malignant brain tumors."

Dr. Chiocca hypothesizes that temporarily suppressing the immune system of glioblastoma patients on a short-term basis could counteract this response and allow the virotherapy work. The study may also expose novel targets to enhance therapy.For more information on the study, the entire manuscript, "NK cells impede glioblastoma virotherapy via NKp30 and NKp46 natural cytotoxicity receptors", is available in Nature Medicine.

This research was conducted in collaboration with researchers from The Ohio State University. It was supported by US National Institutes of Health grants 7U01NS061811, CA069246, CA68458, CA98472 and TL1RR025753. It was also supported by an American Medical Association Foundation Seed Grant and by the Dardinger Neuro-Oncology Laboratory.


Story Source:

The above story is based on materials provided by Brigham and Women's Hospital. Note: Materials may be edited for content and length.


Journal Reference:

  1. Christopher A Alvarez-Breckenridge, Jianhua Yu, Richard Price, Jeffrey Wojton, Jason Pradarelli, Hsiaoyin Mao, Min Wei, Yan Wang, Shun He, Jayson Hardcastle, Soledad A Fernandez, Balveen Kaur, Sean E Lawler, Eric Vivier, Ofer Mandelboim, Alessandro Moretta, Michael A Caligiuri, E Antonio Chiocca. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nature Medicine, 2012; DOI: 10.1038/nm.3013

Cite This Page:

Brigham and Women's Hospital. "Research shows immune system response is detrimental to novel brain cancer therapy." ScienceDaily. ScienceDaily, 4 December 2012. <www.sciencedaily.com/releases/2012/12/121204145655.htm>.
Brigham and Women's Hospital. (2012, December 4). Research shows immune system response is detrimental to novel brain cancer therapy. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2012/12/121204145655.htm
Brigham and Women's Hospital. "Research shows immune system response is detrimental to novel brain cancer therapy." ScienceDaily. www.sciencedaily.com/releases/2012/12/121204145655.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

More Coverage


Patient's Own Immune Cells May Blunt Viral Therapy for Brain Cancer

Nov. 25, 2012 — Doctors now use cancer-killing viruses to treat some patients with lethal, fast-growing brain tumors. Clinical trials show that these therapeutic viruses are safe but less effective than expected. A ... read more

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins